Skip to main content
SpringerLink
Log in

Drug Treatment of the Complications of Cirrhosis in the Older Adult

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Several age-related changes occur in the structure and functions of the liver. The volume of the liver decreases, despite an increase in the size of hepatocytes, suggesting loss of liver cells. There are decreases in hepatic blood flow, the synthesis of urea and cholesterol, and the metabolism of drugs. Moreover, the regenerative capacity of liver becomes less efficient.

Certain caveats are important when treating older patients with liver disease. Strict dietary restrictions, such as a low protein diet, should be avoided in the elderly (unless the patient is encephalopathic) because these patients are often undernourished to start with. Similarly, strict salt restriction should be enforced with caution, since it makes food less palatable and may take away what little desire such patients have to eat. Diuretic doses should be adjusted carefully because of greater risks of azotaemia and electrolyte disturbances in the elderly. Extra vigilance should be exercised in the early detection of infections that are more likely to occur in patients with cirrhosis. For example, spontaneous bacterial peritonitis can be missed in the elderly because of poor systemic (fever, abdominal tenderness) and laboratory responses (leucocytosis). In patients presenting with acute variceal bleeding, it is better to err on the side of underhydration than overhydration because of the risk of congestive heart failure. Vasopressin should be avoided in the elderly, since this drug has a high probability of precipitating an ischaemic event. Older patients do not tolerate β-blockers as well as younger individuals and may require other treatment strategies for the prevention of variceal rebleeding episodes. Hepatic encephalopathy, especially the milder form, needs careful assessment because it can be easily confused with senile dementia syndromes.

Cirrhosis is a premalignant condition and patients are at increased risk of developing hepatocellular carcinoma (HCC), a tumour seen predominantly in the elderly. All patients with cirrhosis should be maintained on a lifelong screening programme consisting of a 6-monthly assessment of α-fetoprotein and an imaging study, since early detection provides the only hope for cure of HCC.

The only definitive treatment of cirrhosis is liver transplantation. Advanced age is not a contraindication to transplantation, and survival in older patients (aged >60 years) is comparable to that in younger individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wynne HA, Cope E, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301

    Article  PubMed  CAS  Google Scholar 

  2. Sato T, Tauchi H. The formation of enlarged and giant mitochondria in the aging process of human hepatic cells. Acta Pathol Jpn 1975; 25: 403–12

    PubMed  CAS  Google Scholar 

  3. Watanabe T, Tanaka Y. Age-related alterations in the size of the human hepatocytes: study of mononuclear and binuclear cells. Virchows Archiv 1982; 39: 9–20

    Article  PubMed  CAS  Google Scholar 

  4. Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg 1969; 117: 881–92

    Article  PubMed  CAS  Google Scholar 

  5. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192–8

    PubMed  CAS  Google Scholar 

  6. James OFW. Parenchymal liver disease in the elderly. Gut 1997; 41: 430–2

    Article  PubMed  CAS  Google Scholar 

  7. Hale WE, Stewart RB, Marks RG. Haematological and biochemical laboratory values in an ambulatory elderly population: an analysis of the effects of age, sex, and drugs. Age Aging 1983; 12: 275–84

    Article  CAS  Google Scholar 

  8. Einarsson K, Nilsell K, Leijd B, et al. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 1985; 313: 277–82

    Article  PubMed  CAS  Google Scholar 

  9. Woodhouse KW, James OFW. Hepatic drug metabolism and aging. Br Med Bull 1990; 46: 22–35

    PubMed  CAS  Google Scholar 

  10. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081–8

    Article  PubMed  CAS  Google Scholar 

  11. Schnegg MI, Lautergerg BH. Quantitative liver function in the liver assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986; 3: 164–71

    Article  PubMed  CAS  Google Scholar 

  12. Liu Y, Guyton KZ, Gorospe M, et al. Age-related decline in mitogen activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes. J Biochem 1996; 271: 3604–7

    CAS  Google Scholar 

  13. Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bc 12 is involved. Cancer Res 1995; 55: 2284–92

    PubMed  CAS  Google Scholar 

  14. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32

    Article  PubMed  CAS  Google Scholar 

  15. Conn HO, Atterbury CE. Cirrhosis. In: Schiff L, Schiff ER, editors. Diseases of the liver. 6th ed. Philadelphia (PA): Lippincott, 1987: 725–864

    Google Scholar 

  16. Wood LJ, Massie D, McLean AJ, et al. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. Hepatology 1988; 8: 831–6

    Article  PubMed  CAS  Google Scholar 

  17. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264–72

    Article  PubMed  CAS  Google Scholar 

  18. Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome. Hepatology 1996; 23: 164–76

    Article  PubMed  CAS  Google Scholar 

  19. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7

    Article  PubMed  CAS  Google Scholar 

  20. Lake JR. The role of transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1745–7

    Article  PubMed  CAS  Google Scholar 

  21. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 1737–42

    PubMed  CAS  Google Scholar 

  22. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9

    Article  PubMed  CAS  Google Scholar 

  23. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495–501

    Article  PubMed  CAS  Google Scholar 

  24. Runyon BA, Van Epps DE. Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 1986; 6: 396–9

    Article  PubMed  CAS  Google Scholar 

  25. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27–31

    Article  PubMed  CAS  Google Scholar 

  26. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716–24

    Article  PubMed  CAS  Google Scholar 

  27. Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic prophylaxis for prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59Suppl. 2: 54–7

    Article  PubMed  Google Scholar 

  28. Pauwels A, Mostefa-Kara N, Debenes B, et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with high risk of infection. Hepatology 1996; 24: 802–6

    PubMed  CAS  Google Scholar 

  29. Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic pro phylaxis for the prevention of bacterial infections in patients with cirrhosis after upper gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655–61

    Article  PubMed  CAS  Google Scholar 

  30. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatology 2000; 32: 142–53

    Article  CAS  Google Scholar 

  31. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113: 1289–94

    Article  PubMed  CAS  Google Scholar 

  32. Terg R, Llano K, Cobas SM, et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration with daily and weekly dosages. J Hepatol 1998; 29: 437–42

    Article  PubMed  CAS  Google Scholar 

  33. Campillo B, Duperyon C, Richardet J-P, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066–70

    Article  PubMed  CAS  Google Scholar 

  34. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–54

    PubMed  Google Scholar 

  35. Pagliaro L, D’Amico G, Sorensen TIA, et al. Prevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117: 59–70

    PubMed  CAS  Google Scholar 

  36. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800–9

    PubMed  CAS  Google Scholar 

  37. Westaby D, Hayes P, Gimson AE, et al. Controlled trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989; 9: 274–7

    Article  PubMed  CAS  Google Scholar 

  38. Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988–93

    Article  PubMed  CAS  Google Scholar 

  39. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63–70

    Article  PubMed  CAS  Google Scholar 

  40. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624–9

    Article  PubMed  CAS  Google Scholar 

  41. Angeli P, Volpin R, Gerunda G, et al. Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1691–7

    Article  Google Scholar 

  42. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870–5

    Article  PubMed  CAS  Google Scholar 

  43. Guevara M, Gines P, Bandi JC, et al. Transjugular portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416–22

    Article  PubMed  CAS  Google Scholar 

  44. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–36

    PubMed  CAS  Google Scholar 

  45. Conn HO. Animal versus vegetable protein diet in hepatic encephalopathy. J Intern Med 1993; 233: 369–71

    Article  PubMed  CAS  Google Scholar 

  46. Camma C, Fiorello F, Tine F, et al. Lactilol in treatment of chronic hepatic encephalopathy: a meta-analysis. Dig Dis Sci 1993; 38: 916–22

    Article  PubMed  CAS  Google Scholar 

  47. Conn HO, Leevy CM, Vlachevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double blind controlled trial. Gastroenterology 1977; 72: 573–83

    PubMed  CAS  Google Scholar 

  48. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999: 340: 745–50

    Article  PubMed  CAS  Google Scholar 

  49. MacMahon M, James OFW. Liver disease in the elderly. J Clin Gastroenterol 1994; 18: 330–4

    Article  Google Scholar 

  50. Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in the elderly. J Am Coll Surg 2001; 192: 38–46

    Article  PubMed  CAS  Google Scholar 

  51. Kew MC. Tumors of the liver. In: Zakin D, Boyer TD, editors. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia (PA): WB Saunders, 1996: 1513–48

    Google Scholar 

  52. Yersiz H, Shaked A, Olthoff K, et al. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995; 60: 790–4

    PubMed  CAS  Google Scholar 

  53. Oh CK, Sanfey HA, Pelletier SJ, et al. Implications of advanced donor age on the outcome of liver transplantation. Clin Transplant 2000; 14: 286–90

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Houston, Texas, USA

    Bhupinder S. Anand

Authors
  1. Bhupinder S. Anand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhupinder S. Anand.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anand, B.S. Drug Treatment of the Complications of Cirrhosis in the Older Adult. Drugs & Aging 18, 575–585 (2001). https://doi.org/10.2165/00002512-200118080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118080-00002

Keywords

Search

Navigation